- BTZ043
-
- $38.00 / 5mg
-
2026-04-21
- CAS:1161233-85-7
- Min. Order:
- Purity: 99.97%
- Supply Ability: 10g
|
| Product Name: | BTZ043 | | Synonyms: | BTZ043;BTZ043 raceMate;2-[(2S)-2-Methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one;BTZ 10526043;PBTZ 169;2-[(3S)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one;BTZ043 (BTZ-043;CS-2310 | | CAS: | 1161233-85-7 | | MF: | C17H16F3N3O5S | | MW: | 431.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1161233-85-7.mol |  |
| | BTZ043 Chemical Properties |
| Melting point | 190-191°C | | density | 1.68 | | storage temp. | -20°C Freezer | | solubility | Chloroform (Slightly), Methanol (Very Slightly) | | form | Solid | | color | White to Pale Yellow |
| | BTZ043 Usage And Synthesis |
| Uses | BTZ043 is an inhibitor of the essential flavo-enzyme Decaprenylphosphoryl-beta-D-ribose 2-epimerase (DprE1). | | Synthesis | Synthesis of 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one (Compound 1) and (2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]decane as 2-(methylsulfanyl)-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one (Compound 1) and (2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]decane. -Trifluoromethyl-4H-1,3-benzothiazin-4-one was carried out in the following general steps: 3.0 g of Compound 1 was suspended in 15 mL of ethanol followed by the addition of 1.5 g of (2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]decane. The reaction mixture was stirred at room temperature and then heated to 50-60°C maintained for 20 minutes. Upon completion of the reaction, it was cooled to room temperature and a light yellow solid was precipitated by adding 100 mL of water. The product was isolated by filtration in 76% yield (calculated based on 2-chloro-3-nitro-5-trifluoromethylbenzamide). | | in vivo | Four weeks of treatment with BTZ043 reduces the bacterial burden in the lungs and spleens by 1 and 2 logs, respectively, at the concentrations used. Additional results suggest that BTZ043 efficacy is time-rather than dose-dependent. Acute (5 g/kg) and chronic (25 and 250 mg/kg) toxicology studies in uninfected mice show that, even at the highest dose tested, there are no adverse anatomical, behavioral, or physiological effects after one month[2]. | | References | [1] Patent: EP2380886, 2011, A1. Location in patent: Page/Page column 8
[2] Patent: WO2011/132070, 2011, A1. Location in patent: Page/Page column 12-13 |
| | BTZ043 Preparation Products And Raw materials |
|